0000000000150187

AUTHOR

Henrik Krarup

showing 3 related works from this author

Treatment of chronic hepatitis B in sub-Saharan Africa: 1-year results of a pilot program in Ethiopia

2018

Background The World Health Organization has set an ambitious goal of eliminating viral hepatitis as a major public health threat by 2030. However, in sub-Saharan Africa, antiviral treatment of chronic hepatitis B (CHB) is virtually unavailable. Herein, we present the 1-year results of a pilot CHB treatment program in Ethiopia. Methods At a public hospital in Addis Ababa, CHB patients were treated with tenofovir disoproxil fumarate based on simplified eligibility criteria. Baseline assessment included liver function tests, viral markers, and transient elastography (Fibroscan). Changes in laboratory markers were analyzed using Wilcoxon signed-rank tests. Adherence to therapy was measured by …

AdultLiver CirrhosisMalemedicine.medical_specialtyAdolescentEpidemiologylcsh:MedicinePilot ProjectsAntiviral therapymedicine.disease_causeAntiviral AgentsYoung Adult03 medical and health sciencesHepatitis B Chronic0302 clinical medicineChronic hepatitisInternal medicineEpidemiologymedicineHumansPilot program030212 general & internal medicineViral hepatitisTenofovirHepatitis B virusmedicine.diagnostic_testbusiness.industryPublic healthlcsh:RGeneral MedicineMiddle AgedViral Loadmedicine.diseaseResource-limited settingsTreatment Adherence and ComplianceTreatment OutcomeFemale030211 gastroenterology & hepatologyEthiopiaTransient elastographybusinessLiver function testsViral hepatitisBiomarkersFollow-Up StudiesResearch ArticleBMC Medicine
researchProduct

Global prevalence and genotype distribution of hepatitis C virus infection in 2015:a modelling study

2017

WOS: 000426979400014

Viremia/epidemiologyPopulation ageingmedicine.medical_specialtyCIENCIAS MÉDICAS Y DE LA SALUDDelphi TechniqueGenotypeVoxilaprevirGenotype Global Health Hepatitis C Eradication Modelling studyMedicina Clínicaddc:616.07Global HealthBioinformatics03 medical and health sciences0302 clinical medicineCost of IllnessEpidemiologyJournal ArticlemedicineGlobal healthPrevalenceHumansViremia030212 general & internal medicineDisease EradicationDisease burdenddc:616HepatologyHepatitis C Chronic/epidemiologybusiness.industryGastroenterologyHepatitis CGlecaprevirHepatitis C Chronicmedicine.diseaseViremia/epidemiology/geneticsPibrentasvirGlobal Health/statistics & numerical dataHCVHEPATITIS C030211 gastroenterology & hepatologyMedicina Critica y de EmergenciaHuman medicinebusinessChronic/epidemiology/genetics/prevention & controlDemography
researchProduct

Hepatitis C virus prevalence and level of intervention required to achieve the WHO targets for elimination in the European Union by 2030: a modelling…

2017

Background Hepatitis C virus (HCV) is a leading cause of liver-related morbidity and mortality worldwide. In the European Union (EU), treatment and cure of HCV with direct-acting antiviral therapies began in 2014. WHO targets are to achieve a 65% reduction in liver-related deaths, a 90% reduction of new viral hepatitis infections, and 90% of patients with viral hepatitis infections being diagnosed by 2030. This study assessed the prevalence of HCV in the EU and the level of intervention required to achieve WHO targets for HCV elimination. Methods We populated country Markov models for the 28 EU countries through a literature search of PubMed and Embase between Jan 1, 2000, and March 31, 201…

Pediatricsddc:616.07medicine.disease_cause0302 clinical medicineCost of IllnessEpidemiologyPrevalenceEPIDEMIOLOGY030212 general & internal medicineSettore SECS-P/01 - Economia PoliticaCIRRHOSISmedia_commonddc:616Antiviral Agents/therapeutic useeducation.field_of_studyINJECT DRUGSGastroenterologyHCV INFECTIONvirus diseasesHepatitis CEmigration and ImmigrationDISEASE BURDENHepatitis CMarkov ChainsEmigration and Immigration/statistics & numerical data030211 gastroenterology & hepatologyViral hepatitisModelling ; Eradication ; European Union ; Hepatitis C ; prevalenceCOUNTRIESmedicine.medical_specialtyHepatitis C virusPopulationUNITED-STATESWorld Health OrganizationAntiviral Agents03 medical and health sciencesSDG 3 - Good Health and Well-beingPEOPLEInternal medicineIntervention (counseling)medicineJournal Articlemedia_common.cataloged_instanceHumansEuropean UnionViremiaEuropean unionDisease EradicationeducationHepatitis C/diagnosis/drug therapy/epidemiology/prevention & controlHepatologybusiness.industryViremia/diagnosis/drug therapy/epidemiology/prevention & controlHepatologymedicine.diseaseVirologyPREVENTIONdigestive system diseasesHuman medicineVIRAL-HEPATITISbusinessLancet Gastroenterology & Hepatology
researchProduct